Novel BCMA-Directed CAR T-Cell Therapy Shows Promising Efficacy in Relapsed/Refractory Multiple Myeloma and AL Amyloidosis
• A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses.
• The novel therapy showed a favorable safety profile with manageable toxicity, including low incidence of severe cytokine release syndrome and no neurotoxicity, even in patients with significant organ dysfunction.
• These promising results have prompted further investigation through ongoing clinical trials, including CARLOTTA001 (NCT05836896) and the CLEAR AL trial, potentially offering new hope for difficult-to-treat hematologic malignancies.
Merit Medical's WRAPSODY Endoprosthesis Receives FDA Approval for Dialysis Patients
• Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis receives FDA premarket approval, paving the way for its commercial launch in the U.S. in 2025.
• The WRAPSODY device is designed to extend long-term vessel patency in dialysis patients by addressing stenosis and thrombosis in arteriovenous (AV) fistulas and grafts.
• Clinical trial results from the WRAPSODY WAVE pivotal trial demonstrated high target lesion primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months.
• The device features a unique cell-impermeable design intended to prevent tissue accumulation, a key contributor to stenosis in hemodialysis patients.
Real-World Data Suggests Elacestrant Offers Similar or Improved Outcomes in Advanced Breast Cancer
• A real-world analysis shows elacestrant demonstrates similar or slightly higher time to treatment discontinuation compared to the EMERALD trial.
• The median real-world time to next treatment with elacestrant was 6.43 months, and time to treatment discontinuation was 4.6 months.
• Patients with PIK3CA pathway alterations experienced worse outcomes with elacestrant, underscoring the need for precision medicine.
• Most patients received elacestrant beyond the second line of treatment, with outcomes remaining consistent across different lines of therapy.
Curcuma Supplements Linked to Reduced Risk of Age-Related Macular Degeneration
• A new study suggests that curcuma-based nutritional supplements (CBNS) may reduce the risk of developing age-related macular degeneration (AMD).
• The research showed significantly lower risks of developing nonexudative, exudative, and advanced nonexudative AMD or geographic atrophy with CBNS use.
• CBNS were also associated with a reduced risk of blindness and the need for anti-VEGF therapy in AMD patients.
• Additional studies are recommended to confirm these findings and explore the mechanisms of CBNS in AMD.
© Copyright 2025. All Rights Reserved by MedPath